Hjem › Tripelnegativ brystkreft › Illinois › Chicago
Kliniske studier for Tripelnegativ brystkreft i Chicago, IL
16 studier for Tripelnegativ brystkreft søker deltakere på steder i og rundt Chicago (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RekruttererFase 1
- University of Chicago Hospital, Chicago
PRE-ISPY Phase I/II Oncology Platform Program
RekruttererFase 1/2
- The University of Chicago Medicine Comprehensive Cancer Center, Chicago
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
RekruttererFase 3
- University of Illinois Cancer Center ( Site 0044), Chicago
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
RekruttererFase 1
- Northwestern University Feinberg School of Medicine, Chicago
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
RekruttererFase 3
- Northwestern Medicine, Chicago
- Rush University Medical Center, Chicago
- University of Chicago Medical Center, Chicago
SMP-3124LP in Adults With Advanced Solid Tumors
RekruttererFase 1/2
- Northwestern Medicine Cancer Center, Chicago
- The University of Chicago, Chicago
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
RekruttererFase 2/3
- Local Institution - 0280, Chicago
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
RekruttererFase 1/2
- Northwestern University, Chicago
A Study of LY4175408 in Participants With Advanced Cancer
RekruttererFase 1
- The University of Chicago Medical Center (UCMC), Chicago
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
RekruttererFase 1
- University of Illinois Hospital and Health Sciences System /ID# 251750, Chicago
- University of Chicago Medical Center /ID# 276271, Chicago
Study of XB010 in Subjects With Solid Tumors
RekruttererFase 1
- University of Chicago Medical Center, Chicago
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
RekruttererFase 1/2
- Northwestern Memorial Hospital, Chicago
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
RekruttererFase 2
- University of Chicago, Chicago
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RekruttererFase 2
- University of Chicago Medical Center, Chicago
A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
RekruttererFase 1
- UChicago Medicine Comprehensive Cancer Center, Chicago
A Study of NX-1607 in Adults With Advanced Malignancies
RekruttererFase 1
- University of Chicago, Chicago
Tripelnegativ brystkreft-studier i andre byer
- Houston, TX42 studier
- New York City, NY31 studier
- Nashville, TN28 studier
- Los Angeles, CA27 studier
- Boston, MA26 studier
- San Antonio, TX23 studier
- St. Louis, MO21 studier
- Arlington, VA20 studier
- Atlanta, GA20 studier
- Dallas, TX18 studier
- Columbus, OH16 studier
- Grand Rapids, MI15 studier
Andre studier i Chicago
- Ikke-småcellet lungekreft61 studier
- Brystkreft59 studier
- Kreft (alle typer)51 studier
- Metastatisk kreft45 studier
- Prostatakreft45 studier
- Lungekreft41 studier
- Fedme41 studier
- Eggstokkreft36 studier
- Kolorektal kreft34 studier
- Slag34 studier
- Hjertesvikt31 studier
- Overvekt29 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.